On September 14, PHARMARON rose 5.52% in regular trading, trading at HK$29.06/share, with turnover of HK$180 million, as CRO/CDMO stocks rallied broadly on continued earnings validation of high industry prosperity.

On the news front, WuXi AppTec's mid-year results significantly beat market expectations and the company sharply raised full-year guidance, reinforcing confidence across the sector. Goldman Sachs expressed an explicitly bullish stance on the Chinese CRO/CDMO recovery trajectory. PHARMARON itself reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with CDMO revenue surging 32.8%. Management raised full-year revenue growth guidance from 12%-18% to 15%-20%, citing strong customer demand and robust order momentum through July and August.

Multiple investment banks recently upgraded PHARMARON's target price. Daiwa raised its target to HK$38.5, Bank of America to HK$38.4, and Morgan Stanley to HK$35.6, all maintaining buy or overweight ratings. JPMorgan also increased its long position to 8.6% of H-shares as of late August.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)